Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood for Bone Marrow Suppression in Elderly MDS/AML
NCT07201233Not yet recruiting
- Sponsor
- Shandong Qilu Stem Cell Engineering
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Hematopoietic Stem Cells
01
Overview
Open-label, single-arm trial of umbilical cord blood in bone marrow suppression, sponsored by Shandong Qilu Stem Cell Engineering. Primary endpoints: Percentage of patients with bone marrow suppression grade < II at 30 days, Hemoglobin level (Hb) at 30 days and 3 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
umbilical cord blood
03
Conditions
bone marrow suppression
Beyond the preview
Go deeper on NCT07201233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201233.